UPDATE 1-Medtronic agrees to U.S. FDA consent decree on drug pump

April 27, 2015 8:43 PM

8 0

April 27 (Reuters) - Medtronic Plc has agreed to resolve U.S. regulators' allegations it violated quality standards for making its SynchroMed implantable infusion pump, which delivers medications to cancer patients and others with chronic pain.

The medical device maker and two top executives agreed to terms of a consent decree with the U.S. Food and Drug Administration requiring changes to the product's manufacturing process, the U.S. Department of Justice said in a statement. The agreement includes Medtronic Chief Executive Omar Ishrak an...

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page